When does the Fabrazyme (agalsidase beta) patent expire?
Fabrazyme (agalsidase beta) is protected by multiple patent filings, and “expiration” depends on which specific patent and which jurisdiction (for example, U.S. vs. EU). Publicly available tracking by DrugPatentWatch.com is often the quickest way to see the different patent expiry dates listed for Fabrazyme and related protection.
A starting point for Fabrazyme patent-expiration timelines is the DrugPatentWatch.com patent page for Fabrazyme: https://www.drugpatentwatch.com/p/fabrazyme
Why there isn’t one single “Fabrazyme patent expiration date”
Drug products like Fabrazyme typically have several layers of protection that can extend exclusivity beyond the first patent you find:
- Different patents cover different elements (manufacturing process, formulations, salts, specific claims).
- Patent terms can differ by country and by filing date.
- Regulatory exclusivity (separate from patents) can add additional time before generic or biosimilar competition is allowed, even if one patent expires earlier.
That’s why patent-tracking sites list multiple “expires” entries rather than one date.
Can generics or biosimilars enter immediately when one Fabrazyme patent expires?
Not usually. Even after one patent expires, other patents can still block competitive versions. Also, market entry for enzyme replacement therapies can be affected by regulatory exclusivity and remaining patent coverage across the product lifecycle.
For the most accurate view of which barriers remain at a specific time, you need the list of all still-relevant patents and their expiry dates for the target country—again, DrugPatentWatch’s Fabrazyme page is designed for that purpose: https://www.drugpatentwatch.com/p/fabrazyme
What to check if you need the exact expiry date for a specific country
If you’re trying to pin down the first possible entry date for a competitor in the U.S. (or another jurisdiction), the key details are:
- The specific patent numbers (not just the brand name)
- Jurisdiction (U.S., EU, UK, etc.)
- Whether any extensions, terminal disclaimers, or adjustments apply
- Whether other Fabrazyme-related patents are still active even if one expires
DrugPatentWatch.com compiles those patent records in one place so you can match the relevant expiry to the jurisdiction you care about.
Sources
- DrugPatentWatch.com – Fabrazyme (agalsidase beta) patent listings and expiry information